Literature DB >> 12465076

An imaging study of parkinsonism among African-Caribbean and Indian London communities.

Michele T M Hu1, K Ray Chaudhuri, Jozef Jarosz, Lidia Yaguez, David J Brooks.   

Abstract

We previously reported on 131 parkinsonian patients of African-Caribbean and Indian origin attending movement disorders clinics in six London Hospitals, of whom approximately 20% manifested atypical parkinsonism with a late-onset, akinetic-rigid predominant syndrome, postural instability and minimal resting tremor refractory to levodopa therapy and dopamine agonists (see Hu et al., Neurology 2000;54[Suppl.3]: A188 and Hu et al., Mov Disord 2000;15[Suppl.3]:S212). To better elucidate the phenotype of these atypical patients (18)FDG/(18)F-dopa positron emission tomography (PET) were performed in a subgroup to look for cortical and striatal metabolic changes suggestive of multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or dementia with Lewy bodies. Magnetic resonance imaging (MRI) rating of cerebral vascular lesion load, putaminal atrophy, and neuropsychological testing were also performed. Discriminant function analysis of (18)F-dopa/(18)FDG striatal metabolism in 43 patients failed to separate atypical ethnic minority from typical Caucasian Parkinson's disease (PD) patients. Additionally, atypical Indian and African-Caribbean patients did not show cortical reductions in glucose metabolism suggestive of PSP, CBD, or DLB. Cerebral vascular lesion load rated in these patients did not differ between atypical and typical PD groups, and none of the atypical patients had MRI changes suggestive of MSA or PSP. Our results suggest the atypical parkinsonian phenotype seen in African-Caribbean and Indian patients represents a levodopa-refractory form of PD separate from MSA or PSP in most patients. Copyright 2002 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12465076     DOI: 10.1002/mds.10261

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

1.  Parkinsonism in a population of northern Tanzania: a community-based door-to-door study in combination with a prospective hospital-based evaluation.

Authors:  Andrea Sylvia Winkler; Esra Tütüncü; Anna Trendafilova; Michael Meindl; John Kaaya; Erich Schmutzhard; Jan Kassubek
Journal:  J Neurol       Date:  2009-12-19       Impact factor: 4.849

2.  Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.

Authors:  V Kaasinen; R P Maguire; H-P Hundemer; K L Leenders
Journal:  J Neurol       Date:  2005-10-18       Impact factor: 4.849

3.  Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta.

Authors:  Ali Sarbazi-Golezari; Hashem Haghdoost-Yazdi
Journal:  Metab Brain Dis       Date:  2021-11-12       Impact factor: 3.584

4.  Camptocormia and Parkinson's disease: MR imaging.

Authors:  Fabrice Bonneville; Frédéric Bloch; Ewa Kurys; Sophie Tezenas du Montcel; Marie-Laure Welter; Anne-Marie Bonnet; Yves Agid; Didier Dormont; Jean-Luc Houeto
Journal:  Eur Radiol       Date:  2008-03-20       Impact factor: 5.315

5.  Associations between Lifestyle Factors and Parkinson's Disease in an Urban Sri Lankan Clinic Study.

Authors:  Ruwani Wijeyekoon; Vindika Suriyakumara; Ranjanie Gamage; Tharushi Fernando; Amila Jayasuriya; Dhanusha Amarasinghe; Harsha Gunasekara; Dharshana Sirisena; Dhammika Amaratunga; Chanaka Muthukuda; Roger A Barker; Caroline Williams-Gray; Ranil De Silva
Journal:  Int Arch Med       Date:  2017-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.